PDF(Pubmed)
Abstract：
OBJECTIVE: This study aimed to validate the Chemotherapy-Induced Alopecia Distress Scale (CADS) in a diverse English-speaking population and patients with endocrine treatment-induced alopecia (EIA).
OBJECTIVE: Chemotherapy and endocrine therapy commonly cause alopecia in breast cancer patients, leading to significant psychological and social challenges. The CADS was developed to assess the psychosocial impact of alopecia, but its generalizability beyond Korean patients requires further investigation.
METHODS: Data from the CHANCE study (NCT02530177), which focused on non-metastatic breast cancer, was used. The cohort included 256 patients, and CADS data were collected at baseline, 6 months after chemotherapy completion, or 12 months after initiating endocrine therapy. The CADS questionnaire comprised 17 items covering physical and emotional health, daily activities, and relationships. Reliability was assessed using Cronbach\'s alpha, and responsiveness was measured by effect size.
RESULTS: The CADS exhibited good reliability, with Cronbach\'s alpha of 0.91 for the overall score, indicating acceptable internal consistency in both chemotherapy (0.89) and endocrine therapy (0.86) groups. Longitudinal responsiveness was supported by an effect size of 0.49 between decreasing satisfaction with hair growth and increasing emotional distress. Cross-sectional validity was confirmed, with effect sizes of 0.91 and 0.92 for satisfaction with hair growth and emotional and activity domains, respectively.
CONCLUSIONS: The CADS is a valid and responsive tool for assessing the psychosocial impact of chemotherapy-induced alopecia and endocrine treatment-induced alopecia in a diverse Western patient population.
OBJECTIVE: Chemotherapy and endocrine therapy commonly cause alopecia in breast cancer patients, leading to significant psychological and social challenges. The CADS was developed to assess the psychosocial impact of alopecia, but its generalizability beyond Korean patients requires further investigation.
METHODS: Data from the CHANCE study (NCT02530177), which focused on non-metastatic breast cancer, was used. The cohort included 256 patients, and CADS data were collected at baseline, 6 months after chemotherapy completion, or 12 months after initiating endocrine therapy. The CADS questionnaire comprised 17 items covering physical and emotional health, daily activities, and relationships. Reliability was assessed using Cronbach\'s alpha, and responsiveness was measured by effect size.
RESULTS: The CADS exhibited good reliability, with Cronbach\'s alpha of 0.91 for the overall score, indicating acceptable internal consistency in both chemotherapy (0.89) and endocrine therapy (0.86) groups. Longitudinal responsiveness was supported by an effect size of 0.49 between decreasing satisfaction with hair growth and increasing emotional distress. Cross-sectional validity was confirmed, with effect sizes of 0.91 and 0.92 for satisfaction with hair growth and emotional and activity domains, respectively.
CONCLUSIONS: The CADS is a valid and responsive tool for assessing the psychosocial impact of chemotherapy-induced alopecia and endocrine treatment-induced alopecia in a diverse Western patient population.
摘要：
目的：本研究旨在验证不同英语人群和内分泌治疗所致脱发（EIA）患者的化疗所致脱发困扰量表（CADS）。
目的：化疗和内分泌治疗通常会导致乳腺癌患者脱发，导致重大的心理和社会挑战。CADS旨在评估脱发的社会心理影响，但其在韩国患者之外的普遍性需要进一步调查。
方法：来自CHANCE研究的数据（NCT02530177），专注于非转移性乳腺癌，被使用。该队列包括256名患者，在基线时收集CADS数据，化疗完成后6个月，或开始内分泌治疗后12个月。CADS问卷包括17个项目，涵盖身体和情绪健康，日常活动,和关系。可靠性使用Cronbach的α进行评估，反应性通过效应大小来衡量。
结果：CADS表现出良好的可靠性，Cronbach的Alpha总分为0.91,表明化疗（0.89）和内分泌治疗（0.86）组的内部一致性可接受。在降低对头发生长的满意度和增加情绪困扰之间，纵向反应性得到了0.49的效应大小的支持。横断面有效性得到确认，效果大小为0.91和0.92，对头发生长、情绪和活动领域的满意度，分别。
结论：CADS是评估不同西方患者人群中化疗诱导的脱发和内分泌治疗诱导的脱发的心理社会影响的有效和反应性工具。
目的：化疗和内分泌治疗通常会导致乳腺癌患者脱发，导致重大的心理和社会挑战。CADS旨在评估脱发的社会心理影响，但其在韩国患者之外的普遍性需要进一步调查。
方法：来自CHANCE研究的数据（NCT02530177），专注于非转移性乳腺癌，被使用。该队列包括256名患者，在基线时收集CADS数据，化疗完成后6个月，或开始内分泌治疗后12个月。CADS问卷包括17个项目，涵盖身体和情绪健康，日常活动,和关系。可靠性使用Cronbach的α进行评估，反应性通过效应大小来衡量。
结果：CADS表现出良好的可靠性，Cronbach的Alpha总分为0.91,表明化疗（0.89）和内分泌治疗（0.86）组的内部一致性可接受。在降低对头发生长的满意度和增加情绪困扰之间，纵向反应性得到了0.49的效应大小的支持。横断面有效性得到确认，效果大小为0.91和0.92，对头发生长、情绪和活动领域的满意度，分别。
结论：CADS是评估不同西方患者人群中化疗诱导的脱发和内分泌治疗诱导的脱发的心理社会影响的有效和反应性工具。
